Getting closer to the in vivo environment with human AB serum

Published: 31 August 2021
FastFacts
Trevor Smith
Trevor Smith
Product Manager, Immune Cell Portfolio, BioIVT
Trevor Smith is the Product Manager for the Immune Cell Portfolio at BioIVT. He has worked extensively in cell and gene therapy and has published methods of T cell expansion on automated bioreactor systems. He has a deep understanding of how to scale-up therapies through process development, GMP lab design and personnel training. In his current role, he uses this knowledge and his immunology background to help customers commercialize new therapies that will provide better patient outcomes.

Watch the video or read the poster to learn:

  • The ideal donor characteristics and pool sizes for high quality serum lots
  • The different production methods that address specific research needs
  • The impact of processing methods on reducing lot-to-lot variability
  • The current and future role of human AB serum in cell and gene therapy

Trevor Smith is the Product Manager for the Immune Cell Portfolio at BioIVT. He has worked extensively in cell and gene therapy and has published methods of T cell expansion on automated bioreactor systems. He has a deep understanding of how to scale-up therapies through process development, GMP lab design and personnel training. In his current role, he uses this knowledge and his immunology background to help customers commercialize new therapies that will provide better patient outcomes.

Please note all fields marked with an * are mandatory

View article

Already registered? Login

If you have any problem accessing our content, please email info@insights.bio